Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen and GlaxoSmithKline welcome NICE Prolia ruling

Amgen and GlaxoSmithKline welcome NICE Prolia ruling

28th October 2010

Amgen and GlaxoSmithKline have welcomed the National Institute for Health and Clinical Excellence's (NICE's) decision to recommend their osteoporosis drug Prolia.

The UK-based healthcare regulator has published finalised guidance which endorses the denosumab-based treatment for preventing osteoporotic fragility fractures in postmenopausal women who are unable to benefit from oral bisphosphonates.

According to figures from the companies, which are co-marketing the drug, 230,000 osteoporosis-related fractures occur in the UK each year, while hip fractures in general are estimated to cost the NHS two billion pounds annually.

Dr Pim Kon, medical director at GlaxoSmithKline, expressed confidence that Prolia can have a transformative effect on patients' quality of life.

John Kearney, general manager at Amgen, added: "We are thrilled that this discovery has led today to patients having access on the NHS to a convenient treatment that really has been shown to be highly effective."

Both Amgen and GlaxoSmithKline have published their third quarter financial reports in the last month, noting positive trends in terms of year-on-year sales developments.ADNFCR-8000103-ID-800198958-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.